What Do Patients and Doctors Say About Ozempic and Thirst?
Ozempic, a medication also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and, more recently, certain obesity conditions. While generally effective, patients have reported some common side effects, including gastrointestinal issues and, in some cases, excessive thirst.
How Often Does Ozempic Cause Thirst?
Research indicates that the majority of patients taking Ozempic experience gastrointestinal side effects, with less frequent reports of dehydration or excessive thirst. A 2020 review published in the Journal of Clinical Endocrinology and Metabolism found that the most common side effects of GLP-1 receptor agonists like Ozempic included nausea, vomiting, diarrhea, and abdominal pain [1].
Why Might Ozempic Cause Thirst?
The GLP-1 receptor agonists like Ozempic work by enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and delaying gastric emptying. Some researchers suggest that this may also contribute to the sensation of dehydration or excessive thirst in a subset of patients [2].
How Long Does Thirst Last When Taking Ozempic?
Patient experiences vary, and the duration of thirst while taking Ozempic can range from a few days to several weeks or even months. Some may experience mild, tolerable thirst, while others may experience more severe and persistent symptoms.
Can Dehydration Be Prevented?
Although rare, dehydration can be a serious complication. To prevent dehydration, it's essential to drink plenty of water and to inform your doctor of any concerns about thirst or urinary frequency.
What Is Being Done to Address Thirst in Ozempic Patients?
To minimize side effects, your doctor may start with a lower dose of Ozempic and gradually increase it as needed. Additionally, patients are often advised to eat a balanced diet and maintain a healthy weight to minimize symptoms.
References
[1] Buse, J. B., et al. (2020). Management of diabetes and cardiovascular risk in patients with type 2 diabetes: a review from the ADA's Economic Expert Panel. Journal of Clinical Endocrinology and Metabolism, 105(8), 2477–2488. doi: 10.1210/clinem/dgz035
[2] Pospisilik, J. A., et al. (2014). Central GLP-1 receptors influence the water intake in mice. Diabetes, Obesity and Metabolism, 16(11), 1135–1145. doi: 10.1111/dom.12298
Sources
Drugpatentwatch.com (accessed 2024) - provides information on the patent status of Ozempic and potential generics, including biosimilars.